None listed
Conditions
Interventions
Procedure/Surgery : IPL treatments using an acne filter and a 590 nm filter will be applied to one eye each. This study will be conducted as a randomized controlled trial, with random allocation perfo
for “2,” the right eye will receive IPL treatment with the 590 nm filter, and the left eye will receive IPL treatment with the acne filter.
Sponsors
Asan Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Patients who visited the ophthalmology department at Asan Medical Center between the IRB approval date and August 31, 2022 (16 months prior to the study end date of December 31, 2023), diagnosed with dry eye disease associated with meibomian gland dysfunction (MGD) and voluntarily agreed to participate in this clinical trial. Moderate or severe dry eye disease with MGD, diagnosed based on the following criteria: Symptoms of dry eye persisting for at least three months prior to enrollment. Tear Break-Up Time (TBUT) of less than 10 seconds, along with at least one of the following three criteria: a. Reduced or altered meibum secretion upon lid compression, showing turbid or toothpaste-like secretions, or viscous discharge. b. Presence of two or more telangiectasias (small, dilated blood vessels) along the eyelid margin. c. Two or more obstructed meibomian gland orifices. Adult patients aged between 19 and 79 years. Ocular Surface Disease Index (OSDI) score of 23 or higher, indicating a moderate level of symptoms.
Exclusion criteria
Exclusion criteria: Exclusion Criteria: Patients with Sjögren's syndrome. Complete obstruction of meibomian gland orifices in both upper and lower eyelids, resulting in no meibum secretion. Use of cyclosporine, steroids, or antibiotic eye drops within two weeks prior to the examination. Use of lipid-containing eye drops within two weeks prior to the examination. Contact lens use within one month prior to the examination. History of ocular surgery or trauma within the past three months. Planned ocular surgery (including LASIK or LASEK) during the study period. Pregnant or breastfeeding women, and women planning to become pregnant. Allergy to fluorescein or topical anesthetics. Any other conditions deemed inappropriate for the study by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Telangiectasia, Matrix Metalloproteinase-9, Tear Break Up time | — |
Secondary
| Measure | Time frame |
|---|---|
| National Eye Institute scale, Sjögren's International Collaborative Clinical Alliance and Oxford staining score, Meibography, Lipid layer thickness, Schirmer test, meibum color, meibum consistency, Ocular Surface Disease Index, osmolality | — |
Countries
Korea, Republic of
Contacts
Public ContactHun Lee
Asan Medical Center
Outcome results
None listed